2. Academic Validation
  3. Targeting the adenosine A2b receptor in the tumor microenvironment overcomes local immunosuppression by myeloid-derived suppressor cells

Targeting the adenosine A2b receptor in the tumor microenvironment overcomes local immunosuppression by myeloid-derived suppressor cells

  • Oncoimmunology. 2014 Feb 14;3:e27989. doi: 10.4161/onci.27989.
Silvana Morello 1,  Lucio Miele 2
Affiliations

Affiliations

  • 1 Department of Pharmacy; University of Salerno; Salerno, Italy.
  • 2 Cancer Institute and Departments of Medicine and Pharmacology; University of Mississippi Medical Center; Jackson, MS USA.
PMID: 25101221 DOI: 10.4161/onci.27989
Abstract

Emerging evidence suggests that the adenosine A2b receptor (ADORA2B, also known as A2bR) plays a pivotal role in tumor progression. We have recently demonstrated that blocking A2bR stimulates T cell-mediated immunosurveillance in a melanoma model by impairing the influx of myeloid-deriver suppressor cells (MDSCs) into the tumor microenvironment. This results in robust antineoplastic effects, which can be abrogated by the adoptive transfer of MDSCs.

Keywords

A2bR; MDSCs; immunosuppression; immunotherapy; tumor microenvironment.

Figures
Products